The placebo-controlled BROADEN2 study is evaluating three doses of KT-621, a STAT6 degrader, in atopic dermatitis. He said Kymera expects its results to fall “in that ballpark” of prior dupilumab atopic dermatitis studies, while noting that differences in trial populations make direct comparisons difficult. Kymera is developing KT-621 as an oral therapy for Type 2 inflammatory diseases, including atopic dermatitis, asthma, eosinophilic esophagitis, chronic spontaneous urticaria and other conditions. Mainolfi said asthma recruitment is progressing well but is not expected to match the pace of enrollment in atopic dermatitis. The atopic dermatitis study includes adolescents ages 12 and older, and Mainolfi said the company is preparing for studies in younger patients, subject to discussions with regulators.